1. Home
  2. AZTA vs GERN Comparison

AZTA vs GERN Comparison

Compare AZTA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AZTA
  • GERN
  • Stock Information
  • Founded
  • AZTA 1978
  • GERN 1990
  • Country
  • AZTA United States
  • GERN United States
  • Employees
  • AZTA N/A
  • GERN N/A
  • Industry
  • AZTA Industrial Machinery/Components
  • GERN Biotechnology: Pharmaceutical Preparations
  • Sector
  • AZTA Technology
  • GERN Health Care
  • Exchange
  • AZTA Nasdaq
  • GERN Nasdaq
  • Market Cap
  • AZTA 2.2B
  • GERN 2.5B
  • IPO Year
  • AZTA 1995
  • GERN 1996
  • Fundamental
  • Price
  • AZTA $48.60
  • GERN $3.88
  • Analyst Decision
  • AZTA Buy
  • GERN Strong Buy
  • Analyst Count
  • AZTA 5
  • GERN 10
  • Target Price
  • AZTA $63.60
  • GERN $7.05
  • AVG Volume (30 Days)
  • AZTA 1.2M
  • GERN 6.7M
  • Earning Date
  • AZTA 02-05-2025
  • GERN 11-07-2024
  • Dividend Yield
  • AZTA N/A
  • GERN N/A
  • EPS Growth
  • AZTA N/A
  • GERN N/A
  • EPS
  • AZTA N/A
  • GERN N/A
  • Revenue
  • AZTA $656,323,000.00
  • GERN $29,480,000.00
  • Revenue This Year
  • AZTA N/A
  • GERN $32,021.10
  • Revenue Next Year
  • AZTA $6.17
  • GERN $298.14
  • P/E Ratio
  • AZTA N/A
  • GERN N/A
  • Revenue Growth
  • AZTA N/A
  • GERN 9199.68
  • 52 Week Low
  • AZTA $38.82
  • GERN $1.64
  • 52 Week High
  • AZTA $69.16
  • GERN $5.34
  • Technical
  • Relative Strength Index (RSI)
  • AZTA 60.69
  • GERN 46.32
  • Support Level
  • AZTA $43.97
  • GERN $3.75
  • Resistance Level
  • AZTA $47.46
  • GERN $4.00
  • Average True Range (ATR)
  • AZTA 1.88
  • GERN 0.15
  • MACD
  • AZTA 0.07
  • GERN -0.00
  • Stochastic Oscillator
  • AZTA 73.56
  • GERN 40.00

About AZTA Azenta Inc.

Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: